Every material Form 8-K Cencora has filed with the SEC since August 27, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cencora reorganized its operating model and will report three segments starting in fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The company also furnished unaudited revised segment results for fiscal 2026 and 2025 under the new structure, which show total revenue of $337.4 billion and total segment operating income of $4.8 billion for fiscal 2026, up from $321.3 billion and $4.2 billion in fiscal 2025.
Beginning in the first quarter of fiscal 2027, reporting segments are Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
Fiscal 2026 total revenue was $337,397,299 thousand, compared with $321,332,819 thousand in fiscal 2025
Fiscal 2026 total segment operating income was $4,813,047 thousand, compared with $4,222,973 thousand in fiscal 2025
MWI Animal Health, Profarma and other PharmaLex components are in Other, a non-reportable category where the company is exploring strategic alternatives
Cencora reported fourth-quarter fiscal 2026 revenue of $88.4 billion, up 5.5 percent, and full-year revenue of $337.4 billion, up 5.0 percent. The company also announced a 10 percent increase in its quarterly dividend and projected fiscal 2027 adjusted diluted earnings per share to be between $19.40 and $19.75.
Fourth-quarter fiscal 2026 revenue increased 5.5 percent to $88.4 billion compared to the prior year period.
Full-year fiscal 2026 GAAP diluted EPS was $17.95, and adjusted diluted EPS was $17.97.
The quarterly dividend was increased by 10 percent to $0.66 per common share, payable on November 30, 2026.
Fiscal 2027 adjusted diluted EPS is expected to range from $19.40 to $19.75, reflecting growth of 8 percent to 10 percent.
Cencora signed a merger agreement to acquire American Oncology Network (AON), valuing AON at an enterprise value of $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The same day, Cencora said its fiscal 2026 adjusted diluted EPS is now expected to be at least $17.90, at the high end of its prior $17.75 to $17.95 range, and that the deal is expected to be accretive to adjusted diluted EPS in the second year after closing.
Enterprise value of $2.4 billion: $2.3 billion at closing plus up to $100 million in CVRs
Cencora expects to pay about $1.7 billion to raise its AON stake to 75%, assuming holders keep up to 25% through an equity rollover
Fiscal 2026 adjusted diluted EPS now expected to be at least $17.90, the high end of the prior $17.75 to $17.95 range
Fiscal 2027 expectations to be discussed on the fourth quarter fiscal 2026 earnings call on November 4, 2026
Cencora's Board appointed Robert E. Sanchez, former Chair and CEO of Ryder System, as a director effective October 1, 2026, expanding the board from ten to eleven members. The filing describes this as a board governance change and does not report any financial results or guidance.
Board appointed Robert E. Sanchez on September 24, 2026; effective date October 1, 2026
Board increased from ten to eleven members to accommodate the appointment
Sanchez will receive the same compensation as other non-employee directors; he has not been named to any committee
Sanchez retired as Chair and CEO of Ryder System in March 2026 and currently serves on the Texas Instruments board
Cencora director Lorence H. Kim informed the company on August 13, 2026 of his intent to resign from the Board effective immediately. He cited his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and the need to devote more time to that role, and said the resignation involves no disagreement with the company on its operations, policies or practices.
Resignation from the Board of Directors is effective immediately, informed on August 13, 2026 after the quarterly board meeting.
Dr. Kim cited his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. as the reason.
The filing states there was no disagreement with the company on operations, policies or practices.
On July 31, 2026, Cencora and its subsidiary Innomar Strategies entered into an amended and restated credit agreement that raises the commitments on its multi-currency revolving credit facility from $5.5 billion to $7.0 billion and extends the maturity date to July 2031. The same day, the company amended its receivables securitization facility, reducing its size from $1.5 billion to $1.0 billion while increasing the accordion feature to $1.0 billion, which gives the company the option to increase commitments by that amount, subject to bank approval.
Revolving credit facility commitments increase from $5.5 billion to $7.0 billion, with maturity extended to July 2031.
Interest on revolver borrowings ranges from 69.5 to 110 basis points over Term SOFR and other benchmark rates, based on public debt ratings.
Receivables securitization facility decreases from $1.5 billion to $1.0 billion; accordion feature increases from $500 million to $1.0 billion.
Both agreements are dated July 31, 2026 and were filed as Exhibits 10.1 and 10.2.
Cencora reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026, with revenue up 5.1 percent to $84.8 billion and GAAP diluted EPS up 11.9 percent to $3.94. The company raised its fiscal 2026 adjusted diluted EPS guidance to $17.75 to $17.95 from $17.70 to $17.90, and it repurchased $1 billion of shares during the quarter.
Revenue of $84.8 billion, up 5.1 percent year over year; GAAP diluted EPS of $3.94 versus $3.52 a year earlier
Adjusted diluted EPS of $4.48, up 12.0 percent from $4.00
Fiscal 2026 adjusted diluted EPS guidance raised to $17.75 to $17.95 from $17.70 to $17.90
Repurchased $1 billion of shares in the quarter; quarterly cash dividend of $0.60 per share payable August 31, 2026
Cencora said Chief Human Resources Officer Silvana Battaglia will retire effective July 12, 2026, after seven years, and will serve in an advisory capacity through the end of 2026. Samantha Hammock, formerly CHRO at Verizon Communications, will succeed her as Executive Vice President and Chief Human Resources Officer effective July 13, 2026. The filing says the retirement was not due to any disagreement with the company's operations, policies or practices, and it reports no financial figures.
Silvana Battaglia retires as EVP and Chief Human Resources Officer effective July 12, 2026
Samantha L. Hammock joins as EVP and CHRO effective July 13, 2026, reporting to CEO Robert P. Mauch
Hammock most recently served as EVP and CHRO at Verizon Communications; Battaglia advises through end of 2026
Filing states the retirement was not the result of a disagreement with the company
Cencora appointed Eva C. Boratto, currently CFO of Bath & Body Works, as Executive Vice President and Chief Financial Officer, effective June 29, 2026, succeeding James F. Cleary, who is retiring and will advise through the end of 2026. The company also reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90 and its long-term growth targets.
Eva C. Boratto succeeds James F. Cleary as CFO, effective June 29, 2026; Cleary serves in an advisory role through the end of 2026
Boratto's compensation includes a $1,000,000 base salary, a 100% annual bonus target, a $2,000,000 one-time sign-on bonus, and a $6,000,000 restricted stock unit award
Fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90 was reaffirmed; it was previously updated on May 21, 2026 from $17.65 to $17.90 after share repurchases
Cencora reported fiscal second-quarter results for the period ended March 31, 2026, with revenue up 3.8% year over year to $78.4 billion and adjusted diluted EPS up 7.5% to $4.75. GAAP diluted EPS of $8.40 was boosted by a $1.1 billion remeasurement gain tied to its OneOncology acquisition. The company raised its fiscal 2026 adjusted diluted EPS guidance to $17.65 to $17.90 and expects to repurchase $1 billion in shares by the end of calendar 2026.
Revenue of $78.4 billion, up 3.8% year over year; adjusted diluted EPS of $4.75 vs. $4.42 a year earlier
GAAP diluted EPS of $8.40 vs. $3.68 a year earlier, including a $1.1 billion gain on the OneOncology remeasurement
Fiscal 2026 adjusted diluted EPS guidance raised to $17.65 to $17.90 from $17.45 to $17.75
Cencora expects to repurchase $1 billion in shares by end of calendar 2026; quarterly dividend of $0.60 per share payable June 1, 2026
Cencora said Chief Financial Officer James F. Cleary will retire effective June 30, 2026, and that the decision was not due to any disagreement with the company. The company also reaffirmed its adjusted diluted EPS guidance range of $17.45 to $17.75 for fiscal 2026, and it has engaged an executive search firm to find a successor.
Cleary, 62, retires as Executive Vice President and CFO effective June 30, 2026, and has served as CFO since November 2018
Cleary will serve in an advisory capacity through the end of 2026 to support the transition
Fiscal 2026 adjusted diluted EPS guidance of $17.45 to $17.75 was reaffirmed, not changed
Cencora has engaged an executive search firm to evaluate internal and external candidates
Cencora closed an underwritten public offering of $3.0 billion in senior notes on February 13, 2026, with maturities from 2029 to 2056. The company intends to use the net proceeds to repay amounts outstanding under a 364-day term credit agreement dated January 12, 2026, which helped fund its acquisition of OneOncology, and any remaining proceeds for general corporate purposes. The notes add to the company's debt, and the filing states they are unsecured and rank equal with its other unsecured debt.
Five tranches total $3.0 billion: $500 million due 2029 at 3.950%, $500 million due 2030 at 4.250%, $500 million due 2033 at 4.600%, $1.0 billion due 2036 at 4.900%, and $500 million due 2056 at 5.650%.
Net proceeds are intended to repay the 364-day term credit agreement dated January 12, 2026, used partly to fund the OneOncology acquisition.
The notes are unsecured and structurally subordinated to liabilities of the company's subsidiaries, including trade payables.
Interest is payable semiannually, starting May 15, 2026 for the 2030 notes and August 13, 2026 for the other tranches.
Cencora reported fiscal first-quarter 2026 revenue of $85.9 billion, up 5.5% year over year, with GAAP diluted EPS of $2.87 (up 14.8%) and adjusted diluted EPS of $4.08 (up 9.4%). The company raised its adjusted operating income growth guidance to 11.5% to 13.5% and reaffirmed adjusted diluted EPS guidance of $17.45 to $17.75, citing the OneOncology acquisition and U.S. Healthcare Solutions performance.
Revenue of $85.9 billion for the quarter ended December 31, 2025, up 5.5% year over year
GAAP diluted EPS of $2.87 versus $2.50 a year earlier; adjusted diluted EPS of $4.08 versus $3.73
Adjusted operating income growth guidance raised to 11.5% to 13.5% from 8% to 10%; adjusted diluted EPS guidance reaffirmed at $17.45 to $17.75
OneOncology majority stake acquired February 2, 2026 for approximately $4.6 billion in cash, funded with new debt
Cencora, Inc. appointed Ellen G. Cooper as an independent director effective January 20, 2026, increasing the board from ten to eleven members. Ms. Cooper is Chairman, President and Chief Executive Officer of Lincoln Financial, and she has not yet been named to any board committee.
Board appointment made January 20, 2026; the board increased from ten to eleven members
Ms. Cooper is Chairman, President and CEO of Lincoln Financial and previously worked at Goldman Sachs Asset Management and AEGON Americas
Her compensation matches other non-employee directors and will be pro-rated until the 2026 Annual Meeting of Stockholders
No committee assignments have been made at this time
On January 12, 2026, Cencora entered into two term loan agreements totaling $4.5 billion to help fund its proposed acquisition of the majority of OneOncology equity it does not already own, and to repay OneOncology debt. The company also increased its revolving credit commitments by $1.0 billion to $5.5 billion. The loans add debt that shareholders will bear, and funding is subject to completion of the acquisition.
$1.5 billion senior unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent: $500 million maturing two years after drawdown and $1.0 billion maturing three years after drawdown
$3.0 billion 364-day senior unsecured term loan with Citibank, N.A. as administrative agent
Revolving credit commitments increased by $1.0 billion to $5.5 billion
Leverage covenant of 4.00 to 1.00, which may be raised to 4.50 to 1.00 after closing a material acquisition; $4.5 billion in bridge financing commitments reduced to zero
Cencora reported fiscal fourth-quarter revenue of $83.7 billion, up 5.9%, but a GAAP net loss attributable to the company of $340 million, or $(1.75) per diluted share, driven by a $723.9 million PharmaLex goodwill impairment. Adjusted diluted EPS rose 15.0% to $3.84, and the company raised its long-term guidance and expects fiscal 2026 adjusted diluted EPS of $17.45 to $17.75, a 9% to 13% long-term EPS growth target.
Q4 revenue $83.7 billion, up 5.9%; fiscal 2025 revenue $321.3 billion, up 9.3%
Q4 GAAP diluted EPS $(1.75) versus $0.02 a year earlier; adjusted diluted EPS $3.84, up 15.0%
Fiscal 2026 adjusted diluted EPS guidance of $17.45 to $17.75 versus $16.00 in fiscal 2025
Quarterly dividend raised 9% to $0.60 per share, payable December 1, 2025
Cencora amended its senior unsecured term loan, moving the maturity from January 2, 2028 to October 1, 2027 and changing the interest rate terms. It also amended its uncommitted money market credit line with Société Générale, setting borrowing limits of $500 million or $750 million depending on the time of year. The filing describes financing terms only and does not report new borrowing amounts or effects on earnings.
Term loan maturity moved from January 2, 2028 to October 1, 2027
Term loan margins range from 62.5 to 125.0 basis points over adjusted Term SOFR, based on public debt ratings
Money Market Facility borrowing limit is $500 million from April 1 to December 1 and $750 million from December 1 to March 31
Both amendments were entered into on September 5, 2025, and the Money Market Facility may be decreased or terminated at any time without prior notice
Cencora's board appointed director D. Mark Durcan as Chairman, effective October 1, 2025, succeeding Steven H. Collis, who is retiring as Executive Chairman and as a director at the end of the fiscal year ending September 30, 2025. The filing says Collis's retirement was not due to any disagreement with the company on its operations, policies or practices, and the board will shrink from 11 to 10 directors. The filing reports no financial results, so the change is a governance and leadership update rather than a change in company performance.
D. Mark Durcan named Chairman of the Board, effective October 1, 2025
Durcan has been a director since September 2015 and Lead Independent Director since March 2023
Steven H. Collis retires as Executive Chairman and director at the end of the fiscal year ending September 30, 2025
Board size reduced from 11 to 10 directors upon Collis's retirement
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cencora filing is on SEC EDGAR ↗. 8-K briefs of other companies →